Irreversible Electroporation for Unresectable Hepatocellular Carcinoma: Initial Experience

• Published in: Cardiovascular and interventional radiology 2019-04, Vol.42 (4), p.584-590
• Main Authors: Kalra, Naveen, Gupta, Pankaj, Gorsi, Ujjwal, Bhujade, Harish, Chaluvashetty, Shreedhara B., Duseja, Ajay, Singh, Virendra, Dhiman, Radha K., Chawla, Yogesh K., Khandelwal, Niranjan
• Format: Article
• Language: English
• Subjects: Ablation; Adult; Aged; Aged, 80 and over; ANESTHESIA; BIOMEDICAL RADIOGRAPHY; Carcinoma, Hepatocellular - mortality; Carcinoma, Hepatocellular - pathology; Carcinoma, Hepatocellular - surgery; Cardiology; Cirrhosis; Clinical Investigation; Complications; COMPUTERIZED TOMOGRAPHY; ELECTRIC FIELDS; Electroporation; Electroporation - methods; Etiology; Female; Follow-Up Studies; Hepatocellular carcinoma; HEPATOMAS; HIGH-VOLTAGE PULSE GENERATORS; Humans; Imaging; Interventional Oncology; LIVER; Liver cancer; Liver cirrhosis; Liver Cirrhosis - complications; Liver Cirrhosis - mortality; Liver Cirrhosis - pathology; Liver Cirrhosis - surgery; Liver Neoplasms - mortality; Liver Neoplasms - pathology; Liver Neoplasms - surgery; Male; Medicine; Medicine & Public Health; Middle Aged; MORTALITY; MULTIVARIATE ANALYSIS; Neoplasm Recurrence, Local - mortality; NMR IMAGING; Nuclear Medicine; Patient Safety; PATIENTS; Portal vein; Progression-Free Survival; PULSES; Radiology; RADIOLOGY AND NUCLEAR MEDICINE; RADIOWAVE RADIATION; Retrospective Studies; SURGERY; Thromboembolism; THROMBOSIS; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; Tumors; Ultrasound; VEINS; α-Fetoprotein
• ISSN: 0174-1551; 1432-086X
• DOI: 10.1007/s00270-019-02164-2

Purpose To evaluate the efficacy and safety of irreversible electroporation (IRE) in the treatment of unresectable hepatocellular carcinoma (HCC). Materials and Methods A retrospective study was conducted from September 2014 to June 2017. A total of 21 HCCs in 21 patients with cirrhosis were treated with IRE. There were eight subcapsular or exophytic, ten perivascular and three peribiliary tumors. The median tumor size was 26 mm (range 14–40 mm). The technical success of the procedure was recorded. Median follow-up, median time to local recurrence, median local tumor progression-free survival (PFS) and complications were recorded. Results Technical success was achieved in all the patients. The median follow-up was 10 months (range 2–30 months). The median time to local recurrence and local tumor PFS were 4 months (range 3–4 months) and 7 months (range 3–30 months), respectively. The tumor-related factor that was significantly associated with local PFS was the size. Maximum tumor diameter